Replies to post #211354 on Biotech Values

[DewDiligence]

CHRS’s PR on Humira-IPR ruling:

https://finance.yahoo.com/news/coherus-biosciences-prevails-135-ipr-232917061.html

The PTAB’s decision invalidates all claims of the patent that were directed to a method for treating rheumatoid arthritis by administering 40 mg of HUMIRA subcutaneously every 13 to 15 days.